Chen et al. demonstrated that shRNA-mediated knockdown of Cx43 or Pcdh7 reduced the tumor burden and pharmacological intervention with the gap junction inhibitors meclofenamate and tonabersat decreased growth kinetics of BrM in pre-clinical trials (59) (Figure 2; Box 1). This evidence concerns the gene GJA1 and neoplasm.